Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FeRx evaluates drug delivery technology for cancer:

This article was originally published in Clinica

Executive Summary

FeRx is receiving a grant from the US National Cancer Institute of the National Institutes of Health to assess the effectiveness of its microparticle drug delivery system for treating pancreatic cancer. The San Diego, California firm will evaluate the use of its MagneTarg technology for the targeted delivery of the drug gemcitabine. The microparticles are made of metallic iron and activated carbon and are drawn to the tumour site using a magnetic field.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT065146

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel